Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ehime
Clinical trial register · Japan

Clinical Trials in Ehime, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2516 matching records held by the registry are in this view. Synced 12 Nov 2026, 03:19 UTC
2516
Studies in scope
all four open statuses
1285
Recruiting now
open to new participants
352
Lead sponsors
across recruiting studies
Top sites
Fukuoka 557 Nagoya 513 Sapporo 400 Tokyo 375 Osaka 354
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
GlaxoSmithKline13 Hoffmann-La Roche7 Gilead Sciences5 Novo Nordisk A/S3 Ono Pharmaceutical Co., Ltd.2 AstraZeneca2 Daiichi Sankyo1 Haihe Biopharma Co., Ltd.1 Summit Therapeutics1 Servier Bio-Innovation LLC1 National Cancer Center Hospital East1 Taiho Pharmaceutical Co., Ltd.1 Genentech, Inc.1 Takeda1 Princess Maxima Center for Pediatric Oncology1 Janssen Research & Development, LLC1 Shockwave Medical, Inc.1 Genmab1 Ascentage Pharma Group Inc.1 ARCAGY/ GINECO GROUP1 Mirum Pharmaceuticals, Inc.1 Cleerly, Inc.1
Site location
Fukuoka557 Nagoya513 Sapporo400 Tokyo375 Osaka354 Chiba328 Kashiwa317 Yokohama272 Kobe239 Kyoto231 Hiroshima224 Sendai207 Chūōku202 Matsuyama172 Bunkyō City171 Kanazawa149 Kumamoto147 Okayama133 Kashiwa-shi132 Niigata120 Fukushima114 Kagoshima107 Kanagawa105 Aichi104 Gifu103 Show all 938
All 938 locations
Target enrolment
to

Trials with a site in Ehime

48 of 2516 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
GlaxoSmithKline
Phase 3
800
Ehime, Fukuoka, Gifu, Hokkaido, Kanagawa, Osaka, Tokyo, Toyama
2026-07-27
Recruiting
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
Hoffmann-La Roche
Phase 3
380
Toyohashi, Aichi, Ehime, Gunma, Hyōgo, Kyoto, Numakunai, Okayama
2026-06-23
Recruiting
Takeda
Phase 2
42
Tokyo, Fukui, Hiroshima, Kanagawa, Fukuoka, Hyōgo, Yamanashi, Ehime
2026-04-22
Recruiting
GlaxoSmithKline
Phase 2
200
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Ishikawa, Numakunai
2026-04-15
Recruiting
GlaxoSmithKline
Phase 3
450
Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka
2025-12-03
Recruiting
Summit Therapeutics
Phase 3
900
Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido
2025-11-18
Recruiting
Novo Nordisk A/S
Observational
630
Koriyama-shi, Fukushima, Oita-shi, Oita,, Kumamoto, Aichi, Aomori, Chiba, Chitose, Hokkaido, Ehime
2025-04-15
Recruiting
Gilead Sciences
Phase 3
695
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hyōgo, Kanagawa, Kobe
2025-04-04
Recruiting
Hoffmann-La Roche
Phase 3
600
Asahikawa-shi, Takamatsu, Sendai, Aichi, Aomori, Chiba, Chikushino-shi, Ehime
2025-03-17
Active, closed
Shockwave Medical, Inc.
Not applicable
81
Asahi, Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Miyagi, Nara
2025-03-10
Recruiting
GlaxoSmithKline
Phase 3
520
Shibuya-Ku, Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hyōgo, Ibaraki
2024-12-16
Recruiting
GlaxoSmithKline
Phase 2
393
Chiba, Ehime, Gunma, Hokkaido, Kagawa, Nara, Niigata, Osaka
2024-09-27
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Miyazaki, Aichi, Chiba, Ehime, Fukuoka, Fukuoka-shi, Fukuoka, Himeji-shi, Hyogo, Hokkaido
2024-06-25
Active, closed
GlaxoSmithKline
Phase 3
88
Aichi, Ehime, Fukuoka, Hokkaido, Hyōgo, Kyoto, Mie, Miyagi
2024-06-10
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
61
Aichi, Ehime, Tokyo
2024-04-29
Recruiting
GlaxoSmithKline
Phase 3
864
Aichi, Aomori, Chiba, Ehime, Fukuoka, Gunma, Hokkaido, Hyōgo
2024-03-21
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Maebashi, Sapporo, Hizume, Kawasaki, Yokohama, Ehime, Fukuoka, Gifu
2024-03-13
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Ehime, Kyoto, Okayama, Osaka, Sapporo, Tochigi, Tokyo, Yamagata
2024-02-05
Active, closed
Hoffmann-La Roche
Phase 3
687
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Ishikawa, Kanagawa
2023-09-14
Active, closed
Hoffmann-La Roche
Phase 3
459
Aichi, Aomori, Chiba, Chūō, Ehime, Fukuoka, Hiroshima, Hokkaido
2023-08-08
Active, closed
Gilead Sciences
Phase 3
654
Aichi, Aoba-ku, Bunkyō City, Chiba, Chūōku, Ehime, Fukushima, Kagoshima
2023-05-08
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Koriyama-shi, Fukushima, Koriyama-shi, Kumamoto, Chiba-shi, Chiba, Ehime, Ibaraki, Minato-ku, Tokyo, Mito-shi, Ibaraki
2023-03-01
Active, closed
Daiichi Sankyo
Phase 3
1,233
Ehime, Fukoka, Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kanagawa, Kumamoto
2023-01-11
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto
2022-12-15
Recruiting
National Cancer Center Hospital East
Phase 3
608
Chiba, Ehime, Fukuoka, Gifu, Hirosaki, Hiroshima, Kawasaki, Kitakyushu
2022-11-21
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
100
Ehime, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima, Kanagawa
2022-11-04
Active, closed
Gilead Sciences
Phase 3
1,021
Chiba, Ehime, Fukuoka, Hyōgo, Ishikawa, Kanagawa, Miyagi, Niigata
2022-10-12
Active, closed
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
NCT06696716Pemphigus, Steroid-resistant Pemphigus
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 3
34
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hokkaido, Kagoshima, Kanagawa
2022-08-15
Active, closed
Genentech, Inc.
Phase 3
373
Aichi, Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kanagawa
2022-08-03
Active, closed
Gilead Sciences
Phase 3
443
Aichi, Aoba-ku, Bunkyō City, Chūōku, Ehime, Fukushima, Inamachi, Kagoshima
2022-07-25
Active, closed
Gilead Sciences
Phase 3
623
Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2022-07-20
Recruiting
AstraZeneca
Observational
300
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2022-06-02
Recruiting
ARCAGY/ GINECO GROUP
Phase 2
390
Tokyo, Kashiwanoha, Kurume, Tsukuba, Niigata, Kita-ku, Shimotsuke, Ehime
2022-02-01
Active, closed
AstraZeneca
Observational
1,620
Aichi, Akita, Aomori, Chiba, Ehime, Fukui, Fukuoka, Fukushima
2021-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
333
Ōmura, Ehime, Hokkaido, Osaka, Tokyo
2021-09-22
Active, closed
GlaxoSmithKline
Phase 3
40
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Kagoshima, Kanagawa
2021-06-28
Recruiting
AB122 Platform Study
NCT04999761Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer
DrugsPimitespib·Futibatinib·Domvanalimab·Ramucirumab
Taiho Pharmaceutical Co., Ltd.
Phase 1
917
Aichi, Chiba, Ehime, Hokkaido, Kanagawa, Osaka, Shizuoka, Tokyo
2021-06-01
Active, closed
GlaxoSmithKline
Phase 3
302
Aichi, Chiba, Ehime, Fukushima, Gunma, Hokkaido, Numakunai, Okayama
2020-10-01
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Active, closed
GlaxoSmithKline
Phase 3
242
Chiba, Ehime, Fukui, Gunma, Hiroshima, Hokkaido, Kagawa, Kanagawa
2020-07-14
Active, closed
GlaxoSmithKline
Phase 3
494
Aichi, Aomori, Ehime, Fukuoka, Gifu, Gunma, Hyōgo, Kanagawa
2020-05-07
Active, closed
GlaxoSmithKline
Phase 3
325
Shibuya-Ku, Aichi, Chiba, Ehime, Fukushima, Gifu, Gunma, Hokkaido
2020-04-02
Active, closed
Multicentre Registry of CCTA, IVUS and OCT
NCT04066062Coronary Artery Disease
Cleerly, Inc.
Observational
1,700
Ehime, Hiroshima, Matsuyama, Okayama, Tokyo
2019-10-01
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,064
Bunkyō City, Chiba, Chikushino-shi, Ehime, Fujiidera-shi, Fukuoka, Fukuoka-ken, Fukushima
2019-09-26
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Ehime, Fukuoka, Kanagawa, Niigata, Osaka, Sapporo, Shizuoka, Tokyo
2019-07-15
Active, closed
Hoffmann-La Roche
Phase 3
1,000
Aichi, Ehime, Fukuoka, Hokkaido, Ibaraki, Ishikawa, Miyagi, Niigata
2019-02-28
Active, closed
Hoffmann-La Roche
Phase 3
382
Ehime, Miyagi, Niigata, Numakunai, Okayama, Tokyo, Wakayama
2017-09-20
Rows per page Showing 1–48 of 48
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-japan/city/ehime

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,516 studies in total at the last sync on 12 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 48 of those studies with a site in Ehime.

How many clinical trials are recruiting in Ehime?

22 of the 48 studies on this page are recruiting new participants as of the 12 Nov 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ehime), 48 studies
PhaseStudiesRecruitingShare
Phase 3311264.6%
Phase 26512.5%
Observational428.3%
Phase 1/2316.3%
Not applicable102.1%
Phase 1112.1%
Phase 2/3102.1%
Phase 4112.1%

Most active sponsors

Lead sponsors with the most studies (Ehime)
Lead sponsorStudiesRecruiting
GlaxoSmithKline137
Hoffmann-La Roche73
Gilead Sciences51
Novo Nordisk A/S31
AstraZeneca21
Ono Pharmaceutical Co., Ltd.21
ARCAGY/ GINECO GROUP11
Ascentage Pharma Group Inc.11
Cleerly, Inc.10
Daiichi Sankyo10
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.